Joyce L Moock

Aphios Corporation is an emerging biotechnology company focused on enhancing health through sustainable science. By integrating green enabling technology platforms with biotechnology, Aphios advances drug discovery and manufacturing, targeting improved therapies for cancer, infectious diseases, and central nervous system disorders. The company employs a hybrid business model, developing proprietary therapeutics while licensing enabling technologies. With 87 issued patents and multiple ongoing projects, Aphios is committed to delivering innovative cannabinoid-based drugs that address chronic conditions such as pain, anxiety, and addiction. Generated from the website

Jaedicke Consulting LLC, based in Arlington, MA, specializes in airport traffic forecasting and economic impact analysis, leveraging over 20 years of industry experience. Founded by Elizabeth Jaedicke in 2018, the firm offers tailored forecasting methodologies that consider individual market drivers and utilize the most relevant aviation data sources. In addition to its core services, Jaedicke Consulting examines the intersection of aviation and tourism, providing insights into the economic impact of airports. The firm prides itself on its attention to detail and responsiveness to client needs, holding various certifications as a Disadvantaged Business Enterprise and Woman Business Enterprise across multiple states. Generated from the website

MAKScientific is a Boston-based pharmaceutical company that is dedicated to developing drugs targeting the endocannabinoid system to treat various medical disorders. With a focus on selective targeting of components such as cannabinoid receptors and enzymes, they have a growing portfolio of small molecule modulators that have shown promise in animal models of human disease. One of their advanced drug candidates, AM6545, is a peripherally restricted CB1 receptor antagonist that offers a potential new approach to managing chronic liver disease and metabolic disorders. Seeking a partner for further development and commercialization, MAKScientific has already advanced this drug candidate to the late pre-clinical stage with no adverse pre-clinical data to date.Generated from the website